Alumis reports Q1 net loss ($99M) vs. ($49.8M) last year

Revenue included license revenue of $17.4M for the quarter ended March 31, 2025, related to the collaboration and licensing agreement with Kaken. Assuming successful close of the merger with ACELYRIN, the combined company’s pro forma cash position of approximately $737M as of December 31, 2024 is expected to provide runway to advance its pipeline through multiple planned key clinical data readouts and to fund operating expenses and capital expenditure requirements into 2027.

Confident Investing Starts Here:

• Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter